Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00571766

Enrollment

Registered

2007-12-12

Start date

2007-11-30

Completion date

2008-12-31

Last updated

2009-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension in Pregnancy

Keywords

chronic hypertension in pregnancy, chronic Hypertension

Brief summary

The purpose of this study is to evaluate the effects of oral L-Arginine in pregnant women with chronic hypertension.

Interventions

DRUGL-Arginine

Oral L-Arginine 2g, twice a day for 14 weeks

DRUGPlacebo

Placebo 2 g twice a day for 14 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Pregnant women between 18-20 week of gestation with chronic hypertension

Exclusion criteria

* Maternal or fetal disease

Design outcomes

Primary

Measure	Time frame
to evaluate blood pressure changes in pregnant women with chronic hypertension during oral arginine or placebo treatment in second trimester of gestation.	14 weeks

Secondary

Measure	Time frame
To evaluate if is necessary add a conventional therapy for hypertension, to evaluate the maternal and fetal outcomes and possible complications, to evaluate the safety of L-Arginine.	14 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026